Welcome to our dedicated page for ENDO INTL PLC ORD news (Ticker: ENDPQ), a resource for investors and traders seeking the latest updates and insights on ENDO INTL PLC ORD stock.
Endo International PLC is a global specialty pharmaceutical company committed to enhancing patients' lives and creating value through the development, manufacture, and distribution of quality branded and generic pharmaceutical products. Established in 1997, Endo operates through subsidiaries including Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs, Somar, and Litha. Their business segments include U.S. branded pharmaceuticals, U.S. generic pharmaceuticals, and international pharmaceuticals, with a focus on maximizing stakeholder value through efficient operations and strategic growth opportunities. Endo recently reported financial results for the fourth quarter of 2023, highlighting revenues, losses, and segment performance.
Rhea-AI Summary
Par Pharmaceutical, a subsidiary of Endo International plc, has issued a voluntary recall of seven lots of Treprostinil Injection due to potential silicone particulates in the product solution. The recall is due to the risk of adverse events if the particulate matter reaches the blood vessels, potentially causing serious health issues. Par has not received any reports of adverse events related to the recall. The affected lots were distributed nationwide to wholesalers and hospitals between June 16, 2022, and August 7, 2023. Consumers are advised to contact their healthcare provider if they have experienced any issues related to the product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Endo International plc (ENDPQ) through its operating company Par Pharmaceutical, Inc., has launched ibuprofen-famotidine tablets, a generic version of Horizon Therapeutics' DUEXIS®, to treat arthritis and reduce stomach ulcer risks. The medication targets a $49 million market and carries warnings about cardiovascular and gastrointestinal risks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40%
Tags
-
Rhea-AI Summary
Endo International plc (ENDPQ) expects to complete its financial restructuring by late April 2024 after the confirmation of its Chapter 11 plan of reorganization. The company's assets will be sold to a new entity, Endo, Inc., with a significant reduction in outstanding debt and resolution of prior litigation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.33%
Tags
Rhea-AI Summary
Endo International plc's Par Pharmaceutical, Inc. is recalling a lot of Treprostinil Injection due to potential silicone particulates, with risks of local irritation, swelling, and serious health issues. The recall affects Lot 57014, distributed nationwide from June to October 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Endo International plc (ENDPQ) reported a 10% decrease in total revenues for the fourth quarter of 2023 compared to the same period in 2022. The reported loss from continuing operations was $2.44 billion, a significant increase from the previous year. Adjusted income from continuing operations decreased by 20% in the fourth quarter of 2023. The Branded Pharmaceuticals segment saw an increase in revenues, driven by Specialty Products. However, the Sterile Injectables and Generic Pharmaceuticals segments experienced revenue declines. Endo provided financial guidance for 2024 with uncertainties related to competitive assumptions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
Endo International plc (ENDPQ) resolves DOJ investigations related to Opana® ER marketing, positioning itself for sustained success through financial restructuring and compliance enhancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.57%
Tags
Rhea-AI Summary
Endo International plc (ENDPQ) announced the publication of a consensus study in the Journal of Hand Surgery Global Open, indicating that XIAFLEX has a wide-ranging application for the treatment of Dupuytren's contracture. The study findings suggest a high level of consensus for using XIAFLEX for the treatment of one- or two-finger metacarpophalangeal (MP) joint contractures, most one- or two-finger proximal interphalangeal (PIP) joint contractures, and most combined MP and PIP joint contractures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
80%
Tags
-
Rhea-AI Summary
Paladin Labs Inc., a subsidiary of Endo International plc, announced the availability of XCOPRI (cenobamate tablets) in Canada for the management of partial-onset seizures in adults with epilepsy. The drug received favorable recommendations for public reimbursement in 2023 and the company is working with government payers to ensure patient access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
66.67%
Tags
-
Rhea-AI Summary
Endo International plc (ENDPQ) announced two new presentations related to Dupuytren's contracture and XIAFLEX® during the American Association for Hand Surgery (AAHS) annual meeting. The research, funded by Endo, aims to improve patient outcomes and presents noteworthy results in the treatment of the proximal interphalangeal (PIP) joint with XIAFLEX.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
50%
Tags
Rhea-AI Summary
Endo International plc (OTC: ENDPQ) is on track to conclude its financial restructuring process by filing a proposed Plan of Reorganization, paving the way for a strengthened balance sheet and business transformation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.45%
Tags
FAQ
What is the current stock price of ENDO INTL PLC ORD (ENDPQ)?
The current stock price of ENDO INTL PLC ORD (ENDPQ) is $0.0006 as of May 1, 2024.
What is the market cap of ENDO INTL PLC ORD (ENDPQ)?
The market cap of ENDO INTL PLC ORD (ENDPQ) is approximately 141.1K.
When was Endo International PLC founded?
Endo International PLC was established in 1997 through the acquisition of certain pharmaceutical products, rights, and assets from Dupont Merck Pharmaceutical Company.
What are the business segments of Endo International PLC?
Endo operates through U.S. branded pharmaceuticals, U.S. generic pharmaceuticals, and international pharmaceuticals segments.
What subsidiaries are part of Endo International PLC?
Endo's operating companies include Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs, Somar, and Litha.
How does Endo International PLC maximize stakeholder value?
Endo focuses on employing an efficient operating model with disciplined execution to pursue organic growth opportunities and selective acquisitions.
What was Endo's total revenue in the fourth quarter of 2023?
Endo reported total revenues of $498 million in the fourth quarter of 2023, reflecting a 10% decrease from the previous year.
Which segments of Endo International PLC showed revenue decreases in the fourth quarter of 2023?
The Generic Pharmaceuticals and Sterile Injectables segments experienced revenue decreases, offset by increased revenues in the Branded Pharmaceuticals segment.
What is the strategic focus of Endo International PLC?
Endo aims to deliver quality, life-enhancing therapies by collaborating globally to develop treatments that benefit patients in need.
What is the recent financial achievement of Endo International PLC?
Endo successfully completed its Chapter 11 financial restructuring, reducing outstanding indebtedness and resolving prior litigation overhang.
How can stakeholders stay informed about Endo's latest updates?
Stakeholders can visit the Endo website or connect on LinkedIn to access additional resources and information on the company's operations.
What recent product launch did Par Pharmaceutical, Inc., a subsidiary of Endo International PLC, announce?
Par Pharmaceutical, Inc., launched a generic version of Amgen's DUEXIS®, reinforcing Endo's commitment to offering affordable healthcare choices.
ENDO INTL PLC ORD
OTC:ENDPQ
ENDPQ Rankings
ENDPQ Stock Data
141.13k
233.69M
0.65%
0.21%
8.47%
Drug Manufacturers - Specialty & Generic
Healthcare
United States of America
Dublin